Surrozen, Inc./DE

On April 1, 2024, Surrozen, Inc. (the “ Company ”), announced a clinical data update with respect to its Phase 1a clinical trial of SZN-043 in healthy volunteers and patients with cirrhosis, as well as a private financing with certain institutional investors of shares of its common stock, pre-funded warrants to purchase shares of common stock, and accompanying warrants to purchase shares of common stock (the “ Private Placement ”). As a result, the Company requires additional time to update the disclosures contained in its Annual Report on Form 10-K for the year ended December 31, 2023 (the “ Form 10-K ”) to reflect the Private Placement and the clinical data update, and is not able to complete the preparation, review and filing of the Form 10-K within the prescribed time period without unreasonable effort or expense. Please see the Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission (the “ SEC ”) on April 1, 2024, for further information regarding the clinical data update, and the Current Report on Form 8-K filed by the Company with the SEC on April 2, 2024, for further information regarding the Private Placement. The net proceeds from the closing of the Private Placement (before the exercise of any warrants), combined with current cash, cash equivalents and marketable securities, is expected to fund the Company’s operating and capital expenditures through the first half of 2025. The Company currently expects to file its Form 10-K on or before April 16, 2024, the prescribed due date pursuant to this Form 12b-25

On April 12, 2021, the Securities and Exchange Commission (the “ SEC ”) released a public statement (the “ Public Statement ”) informing market participants that warrants issued by special purpose acquisition companies (“ SPACs ”) may require classification as a liability of the entity measured at fair value, with changes in fair value each period reported in earnings. Consonance-HFW Acquisition Corp. (the “ Company ”) has previously classified its private placement warrants and public warrants (collectively, the “ warrants ”) as equity. For a full description of the Company’s warrants, please refer to the Company’s final prospectus filed in connection with its initial public offering (“ IPO ”) on November 23, 2020 (“ Final Prospectus ”). Management of the Company and the Audit Committee of the Board of Directors of the Company determined that the Company’s previous audited balance sheet related to its IPO on November 23, 2020, its unaudited financial statements for the period of August 21, 2020 (inception) through September 30, 2020 filed on Form 10-Q with the SEC on January 4, 2021, and its audited financial statements for the period of August 21, 2020 (inception) through December 31, 2020 filed on the Company’s Annual Report on Form 10-K (the “ Affected Periods ”) should no longer be relied upon due to changes required for alignment with the SEC’s Public Statement